Neuroethics and Biopolitics of Cognitive Enhancement Biotechnologies
Table of contents
Share
QR
Metrics
Neuroethics and Biopolitics of Cognitive Enhancement Biotechnologies
Annotation
PII
S004287440000231-9-
Publication type
Article
Status
Published
Authors
Olga Popova 
Occupation: The leading researcher – the chair of the department of humanitarian expertize and bioethics, CSc in Philosophy
Affiliation: Institute philosophy of Russian academy of sciences
Address: Russian Federation, Moscow
Pavel Tishchenko
Affiliation: Institute philosophy of Russian academy of sciences
Address: Russian Federation, Moscow
Sergey Shevchenko
Affiliation: Institute of philosophy of Russian academy of sciences
Address: Russian Federation, Moscow
Edition
Pages
96-108
Abstract

The powerful trend to use the achievements of medical science and biotechnologies not only for treatment but also for human enhancement was formed at the turn of the millennia. One manifestation of this trend is the phenomenon of “academic doping”, which is the application of a variety of medical (particularly pharmacological) means for betterment of cognitive capacities. In neurotics, which emerged at the intersection of bioethics and neuroscience, academic doping and related practices are usually named as cognitive enhancement (Cognitive Enhancement, CE) technologies. Modern medicine does not have sufficient knowledge to prove the efficacy and safety of CE means. Therefore, the basic moral principle -"First, do no harm!"- commands medical professionals to refrain from the use of CE products in healthy people. The article notes that the lack of knowledge could be not only quantitative but also qualitative. There is a fundamental contradiction between the requirements of reliability and validity of the obtained in experiments knowledge. This contradiction is interpreted not as a temporary condition, but as a basic one. It represents complexity in organization and activities of human consciousness. The attention deficit and hyperactivity disorder (ADHD) was discussed as a characteristic example of CE technologies medicalization that is going in consumer societies. Specific features of the modern type of biopower were also discussed. CE technologies consumers are constructing themselves as subjects not in power of true knowledge and effective control (as it was the case in classical medicine), but in consumption of signs of body power inscribed by commercials and different kinds of consumerist society mythologies. Biopower spreads as systematic manipulation of signs (J. Baudrillard).

Keywords
biotechnology, cognitive enhancement, human neuroscience, neuroethics, cognitive liberty, autonomy, attention deficit disorder and hyperactivity, reliable knowledge, validity of knowledge, medicalization, biopower, truth, consumer society
Received
17.08.2018
Date of publication
24.09.2018
Number of purchasers
10
Views
1105
Readers community rating
0.0 (0 votes)
Previous versions
S004287440000231-9-1 Дата внесения правок в статью - 31.07.2018
Cite   Download pdf

References

1. Baudrillard, Jean (1991) Le système des objets, Gallimard, 1991 (Russian translation).

2. Hall, Stephen S. (2003) “The quest for a smart pill”, Scientific American, Vol. 289, № 3, pp. 54–57.

3. Yudin, Boris G. (2016) “Technoscience and human enhancement”, Epistemology & Philosophy of Science, T. XLVIII, № 2, pp. 18–27 (in Russian).

4. Yudin, Grigoriy B. (2016) “Life maximization, human enhancement and the spirit of sports: against utilitarian defense of relaxing doping regulations”, Workbooks on Bioethics, Edition 23, Humanitarian analysis of biotechnological human “enhancement projects", ed. by B.G. Yudin, Publishing house of the Moscow humanitarian university, pp.113–131 (in Russian).

5. Kramer, Peter D. (1993) Listening to Prozac: A psychiatrist explores antidepressant drugs and the re-making of the self, Penguin, New York.

6. Latour, Bruno (1984) Les Microbes. Guerre et paix; suivi de Irréductions, Métaillié, Paris (Russian translation).

7. Matters, Gray (2015) “Topics at the intersection of neuroscience and society”, Presidential Commis-sion for the Study of Bioethical Issues, Washington D.C. http://www.bioethics.gov

8. Rabinow, Paul, Rose, Nicolas (2006) “Biopower today”, BioSocieties, Vol. 1, № 2, pp. 195–217.

9. Sahakian, Barbara J., Morein-Zamir, Sharon (2007) “Professor’s little helper”, Nature, № 20, pp. 1157–1159.

10. Sahakian, Barbara J., Morein-Zamir, Sharon (2015) “Pharmacological cognitive enhancement: treatment of neuropsychiatric disorders and lifestyle use by healthy people”, Lancet. Psychiatry, Vol. 2, pp. 357–362 www.thelancet.com.psychiatry

11. Sallivan, Jacqueline A. (2015) “Experimentation in cognitive neuroscience and cognitive neurobiol-ogy”, Handbook of Neuroethics, ed. Clausen J., Levy N., New York, pp. 3–48.

12. Sententia, Wrye (2004) “Neuroethical considerations: Cognitive liberty and converging technologies for improving human conditions”, The Coevolution of Human Potential and Converging Technologies, New York Academy of Sciences, pp. 221–228.

13. Storebo, Ole J., et al. (2015) “Benefits and harms of methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)”, Cochrane Database of Systematic Reviews, Issue 11.

14. Swanson, James M., Wigal, Timothy, Lakes, Kimberley, Volkow, Nora D. (2013) “Attention deficit hyperactivity disorder: Defining a spectrum disorder and considering neuroethical implications”, The Oxford Handbook of Neuroethics, pp. 309–340.

15. Tishchenko, Pavel D. (2016) “Human bioenhancement in the epoch of consumerism”, Workbooks on Bioethics, Edition 23, Humanitarian analysis of biotechnological human “enhancement projects", ed. by B.G. Yudin, Publishing house of the Moscow Humanitarian University, pp. 12–38 (in Russian).

16. Tishchenko, Pavel D., Yudin, Boris G. (2015) “The finest hour of philosophy”, Voprosy Filosofii, Vol. 12 (2015), pp. 198–203 (in Russian).

Comments

No posts found

Write a review
Translate